Abstracts tagged "microparticles and rheumatoid arthritis (RA)"

Abstract Number: 1917 • 2016 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Cells Produce Extracellular Vesicles That Incorporate PD-1 and microRNAs Targeting the PD-1 Pathway in Surrounding Cells
Stinne Greisen^1,2, Yan Yan³, Aida Hansen¹, Morten Venø³, Jens Randel Nyengaard⁴, Malene Hvid⁵, Arlene Sharpe⁶, Jørgen Kjems³ and Bent Deleuran^7,8, ¹Biomedicine, Aarhus University, Aarhus, Denmark, ²Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Interdisciplinari Nanoscience Center (iNANO), Aarhus University, Aarhus, Denmark, ⁴Clinical Medicine, Electro Microscopy Laboratory, Aarhus University Hospital, Aarhus, Denmark, ⁵Department of Clinical Medicine, Aarhus University, Aarhus, Denmark, ⁶Microbiology and Immunobiology, Harvard Medical School, Boston, MA, ⁷Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁸Department of Biomedicine, Aarhus University, Aarhus, Denmark
Background/Purpose: Programmed death-1 (PD-1) is a central marker of T cell exhaustion. Exhausted T cells are present in inflammatory conditions, where they fail to eliminate…
Abstract Number: 2445 • 2014 ACR/ARHP Annual Meeting
A Distinct Profile of Circulating Microparticles Is Associated with Disease Features in Rheumatoid Arthritis Patients and Impairs Endothelial Functionality in Vitro
Javier Rodríguez-Carrio¹, Mercedes Alperi-López², Patricia López¹, Sara Alonso-Castro², Santiago Rubén Carro-Esteban¹, Javier Ballina-García² and Ana Suárez¹, ¹Area of Immunology, Department of Functional Biology, University of Oviedo, Oviedo, Spain, ²Rheumatology Department, Hospital Universitario Central de Asturias, Oviedo, Spain
Background/Purpose Cell-derived microparticles (MPs) could be considered biomarkers of cell damage and activation and they are thought to have a role in cardiovascular (CV) and inflammatory…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].